当前位置: X-MOL 学术Curr. Opin. Immunol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
NextGen cell-based immunotherapies in cancer and other immune disorders.
Current Opinion in Immunology ( IF 6.6 ) Pub Date : 2019-05-06 , DOI: 10.1016/j.coi.2019.03.007
Camillia S Azimi 1 , Qizhi Tang 2 , Kole T Roybal 1 , Jeffrey A Bluestone 3
Affiliation  

T lymphocyte and other cell therapies have the potential to transform how we treat cancers and other diseases that have few therapeutic options. Here, we review the current progress in engineered T cell therapies and look to the future of what will establish cell therapy as the next pillar of medicine. The tools of synthetic biology along with fundamental knowledge in cell biology and immunology have enabled the development of approaches to engineer cells with enhanced capacity to recognize and treat disease safely and effectively. This along with new modes of engineering cells with CRISPR and strategies to make universal 'off-the-shelf' cell therapies will provide more rapid, flexible, and cheaper translation to the clinic.

中文翻译:


癌症和其他免疫疾病的下一代基于细胞的免疫疗法。



T 淋巴细胞和其他细胞疗法有可能改变我们治疗癌症和其他治疗选择很少的疾病的方式。在这里,我们回顾了工程化 T 细胞疗法的当前进展,并展望了细胞疗法作为下一个医学支柱的未来。合成生物学工具以及细胞生物学和免疫学的基础知识使得能够开发出工程细胞的方法,从而增强安全有效地识别和治疗疾病的能力。这与利用 CRISPR 改造细胞的新模式以及通用“现成”细胞疗法的策略一起,将为临床提供更快速、灵活和更便宜的转化。
更新日期:2019-05-06
down
wechat
bug